AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.
Dividend investing rewards patience. The best dividend stocks don't just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course.
The wall of worry continues to grow as investors race into 2026. Concentration risk is one that may not get talked about enough.
| Pharmaceuticals Industry | Healthcare Sector | Robert A. Michael CPA CEO | XWBO Exchange | US00287Y1091 ISIN |
| US Country | 55,000 Employees | 16 Jan 2026 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.